Skip to content

Comparative study on the efficacy and safety of endoscopic cardioconstriction and radiofrequency ablation in the treatment of refractory gastroesophageal reflux disease

Comparative study on the efficacy and safety of endoscopic cardioconstriction and radiofrequency ablation in the treatment of refractory gastroesophageal reflux disease

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088489
Enrollment
Unknown
Registered
2024-08-20
Start date
2024-08-30
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal refractory reflux disease

Interventions

Endoscopic cardioconstriction (ECCL) group:Patients with GERD were treated with endoscopic cardioconstriction.
Radiofrequency ablation (ERFA) group:GERD patients were treated with ERFA.

Sponsors

Shenzhen Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1)18-80 years old; (2) The course of disease =6 months, with typical acid reflux, heartburn and other symptoms, the diagnosis of GERD patients; (3) GERD patients who took double doses of acid suppressive drugs for 8 weeks without relief of symptoms; (4) Agree to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Endoscopic examination reveals esophageal early cancer, >3cm Barrett's esophagus and other precancerous lesions, and advanced-stage cancer of the upper gastrointestinal tract; (2) Patients with a >2cm hiatal hernia, severe reflux esophagitis (LA-C, LA-D grade), combined with esophagogastric varices, esophageal ulcer or stricture, and patients who have had previous gastroesophageal surgery; (3) Patients with achalasia, diffuse esophageal spasm and other esophageal motility disorders, systemic sclerosis, Sjogren's syndrome and other rheumatological and immunological diseases, and eosinophilic esophagitis; (4) Patients with a history of endoscopic or surgical anti-reflux procedures; (5) Patients with coagulation disorders, severe cardiopulmonary diseases, and those who cannot tolerate anesthesia, endoscopy, and treatment; (6) Postpartum women.

Design outcomes

Primary

MeasureTime frame
Gastroesophageal reflux disease questionnaire (GERD-Q) score;

Secondary

MeasureTime frame
Endoscopic LA grading;Endoscopic Hill grading;

Countries

China

Contacts

Public ContactYing Zhu

Shenzhen Hospital of Southern Medical University

zhuying1@smu.edu.cn+86 133 8466 2039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026